# Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

> **NCT01919684** · PHASE1 · COMPLETED · sponsor: **Ligand Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LGD-6972
- **DRUG:** Placebo (Captisol®)

## Key facts

- **NCT ID:** NCT01919684
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-02
- **Final completion:** 2014-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01919684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01919684, "Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01919684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*